News Image

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Provided By GlobeNewswire

Last update: May 20, 2025

There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening

Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers

Read more at globenewswire.com

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (8/11/2025, 8:00:01 PM)

After market: 1.21 +0.03 (+2.54%)

1.18

+0.01 (+0.85%)



Find more stocks in the Stock Screener

Follow ChartMill for more